The TRMT10A Knockout A-673 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the human A-673 rhabdomyosarcoma cell line. This model features disruption of the TRMT10A gene, which encodes a tRNA (guanine(9)-N1)-methyltransferase responsible for the m1G9 modification of specific tRNAs. By eliminating TRMT10A function, this cell line enables detailed investigation of tRNA modification dynamics and their impact on translational control.
The A-673 host cell line was established from a primary rhabdomyosarcoma in a 15-year-old female and harbors a mutant form of the tumor suppressor p53. As a tumorigenic muscle cell line, A-673 serves as a well-characterized model for rhabdomyosarcoma, a pediatric soft tissue sarcoma. Its transformed phenotype and p53 deficiency provide a relevant background for exploring the tumor?suppressive or oncogenic roles of genetic perturbations, including those affecting RNA modification pathways.
TRMT10A functions as a key enzyme in tRNA maturation, catalyzing the N1-methylguanosine modification at position 9 (m1G9) of a subset of tRNAs. This modification is critical for tRNA stability and the fidelity of protein translation, particularly under cellular stress conditions. TRMT10A is regulated by upstream stress signals and mTOR pathway activity. Its downstream effects include maintaining proper tRNA(m1G9) levels, translation fidelity, and stress?responsive protein synthesis. TRMT10A interacts with tRNA substrates and the related methyltransferase TRMT10B. Together with ribosomes and translation initiation factors, this pathway ensures accurate decoding of the transcriptome in response to environmental cues.
In the context of the A-673 cell line, which harbors mutant p53 and exhibits dysregulated stress responses, loss of TRMT10A can exacerbate defects in protein synthesis during stress, potentially altering tumorigenic properties. Although TRMT10A mutations are primarily linked to neurological disorders such as microcephaly, intellectual disability, epileptic encephalopathy, and early?onset diabetes, the A?673 knockout model provides a valuable platform to study fundamental tRNA biology and its intersection with cancer cell stress adaptation. Researchers can dissect how altered tRNA modification patterns influence ribosome function and translation in a p53?deficient background, shedding light on mechanisms of chemoresistance or metabolic reprogramming.
This knockout cell line is suitable for a broad range of functional assays, including Western blotting to confirm TRMT10A depletion and monitor downstream targets, RT?qPCR for assessing tRNA levels, and tRNA modification detection by LC?MS/MS. Protein synthesis assays using puromycin incorporation or polysome profiling can quantify translational changes, while immunofluorescence enables subcellular localization studies. Apoptosis and stress response assays further allow investigation of cellular outcomes upon TRMT10A loss. Whether for modeling neurological or metabolic disease pathways or exploring translational control in cancer, the TRMT10A Knockout A?673 Cell Line is a robust research tool. For more details, please contact Ascent Research.
